Drug Price Trends for MOTION SICKNESS

Average Pharmacy Cost for MOTION SICKNESS

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
MOTION SICKNESS 50 MG TABLET	46122-0536-53	0.06943	EACH	2024-12-18
MOTION SICKNESS 50 MG TABLET	70000-0404-01	0.06943	EACH	2024-12-18
MOTION SICKNESS RLF 25 MG TAB	70000-0097-01	0.11933	EACH	2024-12-18
MOTION SICKNESS RLF 25 MG TAB	46122-0535-51	0.11933	EACH	2024-12-18

Motion Sickness Treatment Market Analysis and Projections

Market Overview

The motion sickness treatment market is poised for significant growth, driven by several key factors including an increase in global travel, the adoption of prescription and over-the-counter (OTC) medications, and advancements in treatment technologies.

Market Size and Growth Projections

• The global motion sickness treatment market is expected to grow at a Compound Annual Growth Rate (CAGR) of around 3% from 2025 to 2030. This growth is anticipated to take the market from an estimated $755.4 million in 2023 to $863.2 million by 2030[4].
• Another projection suggests that the market will reach $525 million by 2031, growing at a CAGR of 2.9% from 2022 to 2031[3].

Regional Analysis

North America

• North America is expected to hold the largest market share in the motion sickness treatment market. The region's growth is driven by increasing tourism, particularly in the United States, and the high adoption of expensive prescription drugs. By 2031, North America is projected to account for approximately 40.2% of the global market share[3].

Asia-Pacific

• The Asia-Pacific region is identified as the fastest-growing market for motion sickness treatments. This growth is fueled by the increasing number of travelers and the rising penetration of prescription motion sickness drugs in the region[1][5].

Europe and Other Regions

• Europe, particularly countries like France, Germany, Italy, and the UK, also show significant growth due to the resurgence of tourism post-pandemic. Other regions, including the Middle East, Africa, and South America, are also expected to contribute to the market's expansion[4].

Market Segmentation

Treatment Type

• The market is segmented by treatment type, including anticholinergics, antihistamines, and other treatments. Anticholinergic drugs, such as scopolamine, are expected to dominate the market, with a projected CAGR of 2.2% from 2023 to 2030[4].
• Antihistamines are also a significant segment, expected to grow at a CAGR of 1.6% over the same period[4].

Distribution Channel

• The distribution channels include retail pharmacies, online pharmacies, and other channels. The rise of online pharmacies has made it easier for consumers to access motion sickness treatments, contributing to market growth[4].

Route of Administration

• Treatments are administered through various routes, including oral, transdermal, and others. Transdermal patches, particularly those containing scopolamine, are gaining popularity due to their convenience and effectiveness[1][5].

Drivers of Market Growth

Increasing Global Travel

• The resurgence of international travel post-pandemic is a major driver. For instance, in 2022, international tourist arrivals reached 700 million between January and September, more than twice the number in the same period of 2021[1].

Adoption of Prescription and OTC Medications

• The increasing adoption of prescription and OTC medications for motion sickness is another key factor. This is particularly evident in developed economies where high-cost prescription drugs are widely used[2][3].

Technological Advancements

• Advances in treatment technologies, including wearable devices that offer acupressure or neuromodulation, provide drug-free alternatives and are appealing to consumers who prefer natural or side-effect-free solutions[4].

Regulatory Support

• Supportive government regulations and approvals have played a crucial role in expanding the market. Regulatory agencies have approved various treatment options, making it easier for manufacturers to introduce new products[4].

Challenges and Restraints

Adverse Side Effects

• One of the significant challenges is the adverse side effects associated with some motion sickness treatments. This has led to a focus on developing new generation drugs that reduce these side effects[5].

Economic Factors

• The economic impact of the COVID-19 pandemic, which led to a significant decline in international travel, has been a restraint. However, as travel restrictions are lifted, the market is expected to recover[1].

Key Players

• Major players in the motion sickness treatment market include Prestige Consumer Healthcare Inc, WellSpring Pharmaceutical Corporation, Caleb Pharmaceuticals Inc, Myungmoon Pharm Co Ltd, and CVS Health. Other notable companies include Baxter International, Inc., GlaxoSmithKline PLC, and Myungmoon Pharma Co. Ltd[1][4].

Future Outlook

Personalized Medicine

• The rise of personalized medicine is expected to influence the development of diverse treatment options, allowing users to choose treatments that best suit their needs and preferences[4].

Telemedicine

• The growing use of telemedicine has facilitated greater access to prescription treatments for motion sickness, enabling more people to obtain appropriate medications before travel[4].

Wearable Technologies

• Innovations in wearable technologies and medical devices are expected to continue driving the market forward. These technologies offer drug-free alternatives and are gaining popularity among consumers[4].

"The rise of personalized medicine has also influenced the development of diverse treatment options, allowing users to choose treatments that best suit their needs and preferences."[4]

Key Takeaways

• The motion sickness treatment market is expected to grow at a CAGR of around 3% from 2025 to 2030.
• North America will hold the largest market share, while the Asia-Pacific region will be the fastest-growing market.
• Anticholinergic drugs are expected to dominate the market, with significant growth in the adoption of transdermal patches.
• Increasing global travel, adoption of prescription and OTC medications, and technological advancements are key drivers of market growth.
• Regulatory support and the rise of personalized medicine and telemedicine are also crucial factors.

FAQs

What is the projected CAGR for the motion sickness treatment market from 2025 to 2030?

The motion sickness treatment market is expected to grow at a CAGR of around 3% from 2025 to 2030[1][2].

Which region is expected to hold the largest market share in the motion sickness treatment market?

North America is expected to hold the largest market share in the motion sickness treatment market[1][3].

What are the main drivers of the motion sickness treatment market?

The main drivers include increasing global travel, the adoption of prescription and OTC medications, technological advancements, and supportive government regulations[1][2][4].

Which treatment type is expected to dominate the market?

Anticholinergic drugs, particularly those administered through transdermal patches, are expected to dominate the market[4][5].

How has the COVID-19 pandemic impacted the motion sickness treatment market?

The pandemic led to a significant decline in international travel, impacting the market. However, as travel restrictions are lifted, the market is expected to recover and grow[1].

What role do wearable technologies play in the motion sickness treatment market?

Wearable technologies offering acupressure or neuromodulation provide drug-free alternatives and are gaining popularity among consumers who prefer natural or side-effect-free solutions[4].

Sources

1. Mordor Intelligence: Motion Sickness Treatment Market - Trends & Size
2. Transparency Market Research: Motion Sickness Treatment Market Analysis Report 2026
3. Allied Market Research: Motion Sickness Treatment Market Forecast| $5.3 Billion by 2031
4. GlobeNewswire: The Global Market for Motion Sickness Treatment, 2024-2030
5. BioSpace: Motion Sickness Treatment Market: Anticholinergic segment is projected to dominate the market